Navigation Links
LX4211 for Diabetes Shown to Reduce Fasting and Post-Prandial Blood Sugar in Healthy Subjects
Date:9/13/2011

THE WOODLANDS, Texas, Sept. 13, 2011 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, reported positive data from a recently completed clinical trial and mechanistic study of LX4211, a dual inhibitor of the sodium glucose transporters 1 and 2 (SGLT1 and SGLT2).  The favorable safety profile and effects on multiple parameters of glycemic control and cardiovascular health in healthy normal subjects support the broad potential of LX4211 in the treatment of diabetes and associated metabolic conditions.

"Newly observed in this study were the effects of LX4211, in healthy volunteers, of decreasing postprandial glucose levels without hypoglycemia and substantially reducing triglycerides," said Brian Zambrowicz, Ph.D., executive vice president and chief scientific officer.  "Notably, the magnitudes of the reductions in triglycerides were similar to current standard of care prescription and clinical-stage medicines. By contrast, reported results of SGLT2-selective compounds have demonstrated minimal or no reductions in postprandial glucose in healthy subjects and minimal or no triglyceride decreases in either healthy normal volunteers or patients with type 2 diabetes."

Results from the study demonstrated that the 400 mg solid oral dose of LX4211 compared to placebo significantly reduced mean changes from baseline in fasting plasma glucose (p=0.005) and post-prandial glucose levels (p<0.001) in parallel with meaningful mean increases from baseline in total and active GLP-1 (p=0.055 and p=0.003, respectively) as well as PYY (p<0.001).  GLP-1 is associated with improved glucose control and decreased food intake through reduction of appetite.  PYY is a gas
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
2. Phase 2 Trial of LX4211 Demonstrates Significant and Rapid Improvements in Multiple Parameters in Type 2 Diabetic Patients
3. Lexicon Presents Data Describing LX4211 Positive Phase 2 Clinical Results and Novel Mechanism of Action for Type 2 Diabetes
4. Lexicon Announces Positive Results from New Clinical Study of LX4211 in Type 2 Diabetes Patients
5. Lexicon Presents LX4211 Mechanism of Action Data at American Diabetes Association Meeting and Announces Commencement of Phase 2b Clinical Trial in Type 2 Diabetes
6. Lexicon Presents LX4211 Clinical Data at European Association for the Study of Diabetes Annual Meeting
7. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
8. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
9. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
10. Isis Initiates Phase 1 Study of ISIS 325568 Targeting Glucagon Receptor to Treat Type 2 Diabetes
11. Diabetes Research Institute Invention Promotes Growth of Stem Cells into Insulin-Producing Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014   Reproductive Medicine ... leader in the field of infertility, presents new ... embryonic screening. The research abstract, released during the ... Medicine (ASRM) meeting in Honolulu, Hawaii ... single gene defect (SGD) pre-implantation genetic diagnosis (PGD). ...
(Date:10/22/2014)... October 22, 2014 A new ... Market (Product type, Form, End user, Application and Geography) ... Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 - ... market. Based on key trends tracked, it is anticipated ... $7.9 billion by 2020, registering a CAGR of 6.2% ...
(Date:10/22/2014)...   BioNano Genomics , the genome mapping ... to purchase an Irys™ System . Among them ... (NCI), NIH Intramural Sequencing Center (NISC) and Genoscope (The ... comprehensive view of a genome was a major ... deliver the scalability or reliability to detect and ...
Breaking Medicine Technology:New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 2New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 3Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 2Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 3Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 4BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 2BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 3
(Date:10/25/2014)... 26, 2014 LunaDress is excited to ... wedding dresses today. According to the company’s CEO, ... especially those dwelling in the UK. The company’s new ... They are all unpretentious and elegant. , These new ... inputs from top dress experts. LunaDress strives to provide ...
(Date:10/25/2014)... (PRWEB) October 26, 2014 Recently, ... best Joomla hosting suppliers of 2014. . According ... among the most excellent suppliers in the world. ... for webmasters to make money from hosting. The ... resources to host the others’ websites under a ...
(Date:10/25/2014)... Top 10 Best SEO Hosting is ... The site has recently compared many hosting companies and ... among the most reliable Linux web hosting companies in ... Best SEO Hosting says, “The hosting suppliers we recommend ... outperform their competitors on hosting features, uptime and server ...
(Date:10/25/2014)... 26, 2014 The past five ... Sugar Cane Growing industry in Australia . ... by extreme weather patterns, volatile commodity prices and ... industry analyst Brooke Tonkin, “Over the period, flooding ... of Australia's sugar cane crop.” Consequently, industry revenue ...
(Date:10/25/2014)... Diego, CA (PRWEB) October 25, 2014 ... synthetic biology, today announced Dr. Xun ... of all Research & Development. , Triton has developed ... high value algae-based proteins. According to Dr. Wang, the ... over traditional expression systems. He says, “Algae are unique ...
Breaking Medicine News(10 mins):Health News:LunaDress Now Release Its Designer Inspired Fashion Wedding Dresses For Customers Dwelling In The UK 2Health News:Top10BestSEOHosting.com: GoDaddy, Bluehost And Hostgator Are Among The Most Excellent Suppliers In The World 2Health News:Top 10 Best SEO Hosting Announces That GreenGeeks.com And HostMonster Are Among The Most Reliable Linux Web Hosting Companies In 2014 2Health News:Sugar Cane Growing in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Sugar Cane Growing in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Triton Algae Innovations Ltd. Names Dr. Xun Wang as President 2Health News:Triton Algae Innovations Ltd. Names Dr. Xun Wang as President 3
... Cosmecueticals, beauty aids that reportedly work like prescription drugs, ... study recently published in the Journal of Cosmetic Dermatology ... provide a visibly noticeable improvement in maturing skin. , ... the lack of skin surface regularity, formation of wrinkles, ...
... 28 Versus,Technology, Inc. ("Versus" or the "Company") ... October 31, 2007, compared to,revenues of $2,177,000 for ... year,ended October 31, 2007, were $5,566,000 compared to ... vary significantly depending on,the timing and delivery of ...
... MB Software,Corporation (OTC Bulletin Board: MBSB) announced ... Equity Partners to issue 490.196 shares of its,Series ... cancellation of,approximately $1,500,000 in debt. The debt was ... affiliates. The preferred stock will,automatically convert into an ...
... gadolinium-containing contrast injections in adults and pediatric patients (those ... to a recent study conducted by researchers at the ... these reactions do occur, most of them are mild, ... study. , Over the past few years, the ...
... Dec. 28 /PRNewswire-FirstCall/ - AlphaRx Inc. (OTC BB:ALRX,- ... for Drug Delivery,Platforms, announce that in order to ... directors, consultants and employees plan to,exercise stock options ... Lee, President and CEO, will cancel 6,000,000 options,granted ...
... 28 Lincare Holdings,Inc. (Nasdaq: LNCR ) today ... and Exchange Commission (the "SEC") a resale shelf registration,statement ... pursuant to the terms,of a registration rights agreement Lincare ... sale of its $275 million principal amount of,convertible senior ...
Cached Medicine News:Health News:Versus Technology Announces Fourth Quarter Results 2Health News:Versus Technology Announces Fourth Quarter Results 3Health News:Versus Technology Announces Fourth Quarter Results 4Health News:Versus Technology Announces Fourth Quarter Results 5Health News:Versus Technology Announces Fourth Quarter Results 6Health News:Versus Technology Announces Fourth Quarter Results 7Health News:MB Software Corporation Reaches Agreement with Keystone Equity Partners 2Health News:Allergic reactions to gadolinium-based contrast agents are rare, study finds 2Health News:AlphaRx Officers and Directors To Exercise Options, Warrants and Retain Shares 2Health News:Lincare Holdings Inc. Reports Intention to File Shelf Registration Statement 2
... including the Ceralas D and SmilePro 980 ... medical, dental, and veterinary environments.,With unsurpassed, optimal ... nm laser series allow controlled tissue ablation ... surgical procedures. Unlike other medical lasers, biolitecs ...
... Assay is a second generation nucleic acid ... in vitro qualitative detection and differentiation of ... uses a family of Gen-Probe's proven technologies ... and Dual Kinetic Assay (DKA). This is ...
... The InTray™ GC is a ... detection of both Neisseria gonorrhoeae and ... a long shelf life and is ... system. Simply inoculate, incubate and ...
... designed for patients with a spherical hyperopia between ... who would benefit from a spherical treatment of ... a myopic endpoint of between -1.00 D and ... improve near vision. CK is unique in that ...
Medicine Products: